Biomedical & Pharmacology Journal最新文献

{"title":"Evaluation of Anti-Hemorrhoidal Activity and Phytochemical Study of Zidarga-6 Capsule","authors":"Chimedragchaa Chimedtseren, Dejidmaa Buyantogtokh, Myadagbadam Urtnasan, Anu Altangerel, Uuganbayar Baatartsogt, Erdenechimeg Chuluunbaatar","doi":"10.13005/bpj/3240","DOIUrl":"https://doi.org/10.13005/bpj/3240","url":null,"abstract":"Traditional Mongolian medicine encompasses various practices for treating hemorrhoids. One of the pharmaceutical formulations is Zidraga-6, which is composed of six active remedies. Aim of the study: The study sought to explore the phytochemical composition of Zidraga-6 and to thoughtfully evaluate its potential effects in a hemorrhoid model using rats. Methods: Thin-layer chromatography (TLC) was employed to identify biologically active compounds, and their concentrations were quantified using UV spectrophotometric methods. The experiment was conducted using a methodology established with a croton oil mixture. In a designated group, a hemorrhoid model was successfully induced in healthy animals using croton oil. Following a 24-hour period after the induction of the model, the Zidraga-6 herbal formulation was administered once daily over the course of eight days. Results: Using thin-layer chromatography (TLC), we identified oleonalic acid, gallic acid, quercetin, capsaicin, and p-methoxycinnamate in the Zidraga-6 capsules. UV spectrophotometric analysis determined the content of bioactive compounds in Zidarga‑6 capsules to be 1.89 ± 0.19 % total triterpene saponins, 1.30 ± 0.12 % flavonoids, and 12.59 ± 0.68 % phenolic compounds. Using thin-layer chromatography (TLC), we identified oleonalic acid, gallic acid, quercetin, capsaicin, and p-methoxycinnamate in the Zidraga-6 capsules. UV spectrophotometric analysis determined the content of bioactive compounds in Zidarga‑6 capsules to be 1.89 ± 0.19 % total triterpene saponins, 1.30 ± 0.12 % flavonoids, and 12.59 ± 0.68 % phenolic compounds. The results of this study indicated that all doses of Zidraga-6 capsules effectively reduced the inflammatory cytokine IL-6 in the rat hemorrhoid model. Furthermore, the levels of the cytokine IL-1β were significantly lowered with the 130 mg/kg and 325 mg/kg doses. Histopathological examination of the recto anal tissue demonstrated that the structural changes, inflammation, and necrosis were significantly diminished with the 130 mg/kg and 325 mg/kg doses of Zidraga-6 capsules when compared to the untreated hemorrhoid model. Conclusions: Zidraga‑6 capsules contain biologically active constituents such as flavonoids, phenolic compounds, and triterpene saponin. Zidraga-6 has demonstrated efficacy in treating hemorrhoids by reducing pro-inflammatory cytokines and decreasing rectal damage.","PeriodicalId":8971,"journal":{"name":"Biomedical & Pharmacology Journal","volume":"18 3","pages":"2102-2112"},"PeriodicalIF":0.0,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147903553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CD133 and CD166 as stem cell markers for predicting the possibility of developing prostatic cancer in cases of benign prostatic hyperplasia","authors":"Khalida I. Noel, Mustafa M. Ibraheem, Basim S. Ahmed, Ahmed F. Hameed, Nibras H. Khamees, Sameh S. Akkila","doi":"10.13005/bpj/1769","DOIUrl":"https://doi.org/10.13005/bpj/1769","url":null,"abstract":"Benign and malignant prostatic diseases are generally well-known in the world. Accordingly, this research is planned to assess the immunohistochemical analysis of CD133 and CD166 in the prostatic epithelium in samples of benign prostatic hyperplasia (BPH) and normal looking epithelium around prostatic adenocarcinoma samples (PCa) and to explore the opportunity of malignant alterations in benign tissue. The prostate samples were divided into 2 groups; 50 BPH samples, and 50 normally looking tissue surrounding prostatic carcinoma samples (NPCA). The samples were treated for immunohistochemical examination of CD133 and CD166. Over expression of CD133 appeared in the BPH group which was statistically significant as compared to NPCA group. Conversely, over expression of CD166 stem cell marker in NPCA group than BPH group as it was significant statistically. CD166 is a stem cell marker for tissue tumorigenicity, while the positive expression of CD133 is not of value for cancer initiation.","PeriodicalId":8971,"journal":{"name":"Biomedical & Pharmacology Journal","volume":"17 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74426393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}